The company's R&D strategy is focused on being the first to launch generic versions of major drugs like Ozempic®/Wegovy™ (from Novo Nordisk) and Abilify Maintena® (from Otsuka/Lundbeck). This highlights a direct and aggressive competitive strategy against major pharmaceutical brands in high-value markets.
Filing excerpt
The Company is working on many other programs, including... on the potential to be first to market for its generics of Abilify Maintena®, Injectafer®, Ozempic®, and Wegovy™.
What this signalsFilings often name leadership changes, deals and spending plans.
Competitors
sec-10kcompetitorNamedGet every 10-K signal for Viatris and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Viatris this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/668f2019-1bc5-4c90-b70f-475ba026d349 returns this record as JSON. POST /v1/companies/enrich returns every signal for viatris.com.
{
"signal_id": "668f2019-1bc5-4c90-b70f-475ba026d349",
"signal_type": "sec-10k",
"signal_subtype": "competitorNamed",
"detected_at": "2026-03-03T06:02:41.098+00:00",
"company": {
"name": "Viatris",
"domain": "viatris.com"
},
"data": {
"detail": "The company's R&D strategy is focused on being the first to launch generic versions of major drugs like Ozempic®/Wegovy™ (from Novo Nordisk) and Abilify Maintena® (from Otsuka/Lundbeck). This highlights a direct and aggressive competitive strategy against major pharmaceutical brands in high-value markets.",
"summary": "Viatris targets first-to-market generics for blockbusters Ozempic®, Wegovy™, and Abilify Maintena®.",
"excerpts": "The Company is working on many other programs, including... on the potential to be first to market for its generics of Abilify Maintena®, Injectafer®, Ozempic®, and Wegovy™.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm",
"filing_date": "2026-02-26",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Competitive intelligence",
"signal_category": "market",
"competitors_mentioned": [
"Novo Nordisk",
"Otsuka",
"Lundbeck",
"Daiichi Sankyo",
"Vifor Pharma"
]
}
}
curl https://signals.autobound.ai/v1/signals/668f2019-1bc5-4c90-b70f-475ba026d349 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"viatris.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.